summari yesterday opportun meet
manag key takeaway follow
seek offset expect step fiscal tax rate
confid deliv organ growth growth
could back-end load op margin target also
remain intact long-range-plan lrp guidanc
unchang comfort mid-
point respect rang vs higher-end previous
growth revis cvg cardiac vascular group attribut
weak lvad left ventricular assist devic expect
transient impact dcb drug coat balloon meta-analysi
rtg restor therapi group mitg minim
invas therapi group perform strongli provid
off-set cvg soft
seek offset expect tax rate increas
januari compani present investor
confer manag said expect
compani target ep growth plan period due
anticip step tax rate next year specif
said base propos tax regul expect
underli tax rate increas y/i
rang accord compani ir propos new tax
regul decemb seek implement hybrid rule
punit compani domicil ou
compani said focus tri off-set
expect tax rate headwind tax plan lower interest
expens share repurchas
confid organ growth growth
could back-end load expect sub
report ep growth clearli disappoint investor
remain confid achiev next year financi
target laid recent investor day includ
annual organ revenu growth annual op margin
improv progress convers top-lin
manag highlight sever key product launch
includ advanc hybrid closed-loop diabet system micra
sens surgic robot low-risk tavr transcathet aortic
valv replac indic understand sever
launch expect lead us believ
mdt growth next fiscal year back-end load
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
guidanc re-affirmed comfort midpoint
notabl updat januari present view reaffirm compani
full-year guidanc includ organ revenu growth
respect howev manag said comfort mid-point
respect rang versu compani prior commentari comfort higher-end
chang primarili result weak cvg see math
impli guidanc roughli mdt op margin adj ep guidanc
remain unchang call
cvg guidanc lower lower outlook cvg busi
/- /- respect manag attribut
downward revis cvg guidanc primarili soft lvad lvad growth expect
declin y/i accord primari driver lvad weak approv
abt pump dt destin therapi receiv fda approv full quarter
earlier expect unfavor dynam lvad recent chang
guidelin depriorit heart transplant patient lvad bridge-to-transpl
popul separ call paclitaxel dcb/de drug elut stent meta-analysi
publish journal american heart associ jaha transient headwind
quarter cvg said data patient inpact admir dcb includ year
data signal increas mortal compani schedul present analysi dataset
linc leipzig intervent cours meet later month seek simultan
public high-profil medic journal understand present addit data
meet held viva vascular intervent advanc late february/earli march note
januari titl bdx/bsx/mdt drug coat balloon stent updat take topic
rtg mitg expect provid off-set cvg growth note strength
compani rtg mitg divis provid off-set cvg henc re-affirm
guidanc would impli rtg mitg come toward high-end
respect guidanc rang refer previous guid rtg growth
/- respect mitg guidanc provid call
growth /- full-year manag said see particular
strength pain stim neurovascular enabl technolog rtg mitg perform
driven new product innov includ compani signia stapler ligasur vessel sealer
capnostream respiratori monitor manag note diabet like sourc upsid
given particularli tough prior year comparison wed note mdt diabet guidanc math
impli roughli
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
